Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States - 27/09/22
Abstract |
Background |
Alcoholic cirrhosis is an advanced form of alcohol-related liver disease. In the United States, between 2010 and 2016, alcohol-related liver disease was the primary cause of nearly 1 in 3 liver transplants, surpassing hepatitis C.
Methods |
We utilized the US Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research database to compare trends in mortality from alcoholic cirrhosis in the United States in 1999 and 2019. We defined mortality from alcoholic cirrhosis as International Classification of Diseases code K70.3 (alcoholic cirrhosis of liver). We calculated mortality rates and mortality rate ratios (MRRs) per 100,000 from alcoholic cirrhosis in 10-year age groups from 25 to 85+ as measures of effect and 95% confidence intervals to test for significance.
Results |
In 1999, there were 6007 deaths from alcoholic cirrhosis among 180,408,769 aged 25-85+ years, yielding a mortality rate of 3.3 per 100,000. In 2019, there were 23,780 deaths from alcoholic cirrhosis among 224,981,167 aged 25-85+ years, yielding a mortality rate of 10.6 per 100,000. The overall MRR of 3.2 was statistically significant. (P < .001), and was apparent in each 10-year age group.
Conclusions |
These alarming trends in mortality from alcoholic cirrhosis in the United States contribute to the formulation of many hypotheses. These require testing in analytic studies designed a priori to do so. Meanwhile, clinical and public health efforts are necessary to curb the epidemics of heavy alcohol consumption and overweight and obesity in the United States that may be contributing to these alarming trends.
Le texte complet de cet article est disponible en PDF.Keywords : Alcoholic cirrhosis, Mortality, Trends, United States
Plan
| Funding: None. |
|
| Conflict of Interest: OT, LF, LM, JF, PP, and RSL have no disclosures. CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; to the Collaborative Institutional Training Initiative, the United States Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within Truist Investments, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 135 - N° 10
P. 1263-1266 - octobre 2022 Retour au numéro
Article précédent
- Racial Disparities Between C-Reactive Protein and COVID-19 In-Hospital Outcomes
- Wenjin Sun
- Emerging from the Pandemic: AAIM Recommendations for Internal Medicine Residency and Fellowship Interview Standards
- Vera P. Luther, David A. Wininger, Cindy J. Lai, Anthony Dao, Maria M. Garcia, Whitney Harper, Timothy M. Chow, Ricardo Correa, Lindsey J. Gay, Lyle Fettig, Bhavin Dalal, Patricia Vassallo, Steven Barczi, Michelle Sweet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?